新型非氟喹诺酮类药物奈莫沙星（TG-873870）与其他喹诺酮类药物对临床分离株的体外比较活性。
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
机构信息
Division of Infectious Diseases, National Health Research Institutes, 35 Keyan Rd. Zhunan, Taiwan 350.
出版信息
Antimicrob Agents Chemother. 2010 Mar;54(3):1338-42. doi: 10.1128/AAC.01197-09. Epub 2010 Jan 11.
Abstract
The in vitro antibacterial activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, against 770 clinical isolates were investigated. Nemonoxacin (tested as its malate salt, TG-875649) showed better in vitro activity than ciprofloxacin and levofloxacin against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenzae. The in vitro activity of TG-875649 was also comparable to or better than that of moxifloxacin against these pathogens, which included ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus and levofloxacin-resistant Streptococcus pneumoniae.
摘要
研究了新型非氟喹诺酮类药物奈莫沙星（TG-873870）对 770 株临床分离菌的体外抗菌活性。奈莫沙星（以马来酸盐形式 TG-875649 测试）对不同种的葡萄球菌、链球菌和肠球菌、淋病奈瑟菌和流感嗜血杆菌的体外活性优于环丙沙星和左氧氟沙星。TG-875649 的体外活性与莫西沙星相当，或优于包括对环丙沙星耐药、耐甲氧西林金黄色葡萄球菌和左氧氟沙星耐药肺炎链球菌在内的这些病原体。
相似文献
1
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Antimicrob Agents Chemother. 2010 Mar;54(3):1338-42. doi: 10.1128/AAC.01197-09. Epub 2010 Jan 11.
2
In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
J Antimicrob Chemother. 2009 Dec;64(6):1226-9. doi: 10.1093/jac/dkp370. Epub 2009 Oct 14.
3
Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
J Antimicrob Chemother. 1999 Nov;44(5):621-7. doi: 10.1093/jac/44.5.621.
4
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
Antimicrob Agents Chemother. 2009 Nov;53(11):4915-20. doi: 10.1128/AAC.00078-09. Epub 2009 Sep 8.
5
Nemonoxacin has potent activity against gram-positive, but not gram-negative clinical isolates.
Clin Ter. 2015 Nov-Dec;166(6):e374-80. doi: 10.7417/T.2015.1903.
6
Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan.
Microb Drug Resist. 2020 Feb;26(2):110-117. doi: 10.1089/mdr.2019.0048. Epub 2019 Aug 30.
7
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
Antimicrob Agents Chemother. 2003 Oct;47(10):3260-9. doi: 10.1128/AAC.47.10.3260-3269.2003.
8
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Eur J Clin Microbiol Infect Dis. 2010 Nov;29(11):1369-75. doi: 10.1007/s10096-010-1009-9. Epub 2010 Jul 25.
9
In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
Antimicrob Agents Chemother. 2006 Jun;50(6):2255-7. doi: 10.1128/AAC.00011-06.
10
In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
Clin Microbiol Infect. 2003 Oct;9(10):997-1005. doi: 10.1046/j.1469-0691.2003.00696.x.
引用本文的文献
1
Comparative In vitro antibacterial activity of nemonoxacin and other fluoroquinolones in correlation with resistant mechanisms in contemporary methicillin-resistant Staphylococcus aureus blood isolates in Taiwan.
Ann Clin Microbiol Antimicrob. 2025 Jan 17;24(1):5. doi: 10.1186/s12941-024-00772-6.
2
Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease.
Sci Rep. 2023 Oct 7;13(1):16954. doi: 10.1038/s41598-023-44188-2.
3
Safety of oral nemonoxacin: A systematic review of clinical trials and postmarketing surveillance.
Front Pharmacol. 2022 Dec 9;13:1067686. doi: 10.3389/fphar.2022.1067686. eCollection 2022.
4
Nemonoxacin Enhances Antibacterial Activity and Anti-Resistance Mutation Ability of Vancomycin against Methicillin-Resistant Staphylococcus aureus in an Dynamic Pharmacokinetic/Pharmacodynamic Model.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0180021. doi: 10.1128/AAC.01800-21. Epub 2021 Dec 13.
5
Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.
Molecules. 2021 Nov 25;26(23):7153. doi: 10.3390/molecules26237153.
6
Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation.
Pharmaceutics. 2021 Aug 18;13(8):1289. doi: 10.3390/pharmaceutics13081289.
7
Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against .
Front Pharmacol. 2021 May 4;12:658558. doi: 10.3389/fphar.2021.658558. eCollection 2021.
8
Efficacy and Safety of Nemonoxacin in Outpatients with Community-Acquired Pneumonia.
Infect Drug Resist. 2020 Jul 2;13:2099-2104. doi: 10.2147/IDR.S248092. eCollection 2020.
9
Activities of Nemonoxacin and Other Antimicrobial Agents Against Human and Isolates and Their Defined Resistance Mechanisms.
Front Microbiol. 2019 Aug 13;10:1890. doi: 10.3389/fmicb.2019.01890. eCollection 2019.
10
The Continuing Threat of Methicillin-Resistant .
Antibiotics (Basel). 2019 May 2;8(2):52. doi: 10.3390/antibiotics8020052.
本文引用的文献
1
Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases.
Antimicrob Agents Chemother. 2009 Jan;53(1):104-11. doi: 10.1128/AAC.00852-08. Epub 2008 Oct 20.
2
The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter.
Trends Microbiol. 2006 Sep;14(9):413-20. doi: 10.1016/j.tim.2006.07.008. Epub 2006 Jul 31.
3
Extended-spectrum beta-lactamases and plasmid-mediated AmpC enzymes among clinical isolates of Escherichia coli and Klebsiella pneumoniae from seven medical centers in Taiwan.
Antimicrob Agents Chemother. 2006 May;50(5):1861-4. doi: 10.1128/AAC.50.5.1861-1864.2006.
4
Antibacterial resistance worldwide: causes, challenges and responses.
Nat Med. 2004 Dec;10(12 Suppl):S122-9. doi: 10.1038/nm1145.
5
The status of antimicrobial resistance in Taiwan among Gram-positive pathogens: the Taiwan Surveillance of Antimicrobial Resistance (TSAR) programme, 2000.
Int J Antimicrob Agents. 2004 Apr;23(4):362-70. doi: 10.1016/j.ijantimicag.2003.09.021.
6
The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000.
Diagn Microbiol Infect Dis. 2004 Mar;48(3):211-9. doi: 10.1016/j.diagmicrobio.2003.10.005.
Zotero 插件